Assessment: botulinum neurotoxin for the treatment of movement disorders (an evidence-based review): Report of the therapeutics and technology assessment subcommittee of the american academy of neurologysymbol

D. M. Simpson, A. Blitzer, A. Brashear, C. Comella, R. Dubinsky, M. Hallett, J. Jankovic, B. Karp, C. L. Ludlow, J. M. Miyasaki, M. Naumann, Y. So

Research output: Contribution to journalArticle

317 Citations (Scopus)

Abstract

To perform an evidence-based review of the safety and efficacy of botulinum neurotoxin (BoNT) in the treatment of movement disorders. A literature search was performed including MEDLINE and Current Contents for therapeutic articles relevant to BoNT and selected movement disorders. Authors reviewed, abstracted, and classified articles based on American Academy of Neurology criteria (Class I-IV). The highest quality literature available for the respective indications was as follows: blepharospasm (two Class II studies); hemifacial spasm (one Class II and one Class III study); cervical dystonia (seven Class I studies); focal upper extremity dystonia (one Class I and three Class II studies); focal lower extremity dystonia (one Class II study); laryngeal dystonia (one Class I study); motor tics (one Class II study); and upper extremity essential tremor (two Class II studies). Botulinum neurotoxin should be offered as a treatment option for the treatment of cervical dystonia (Level A), may be offered for blepharospasm, focal upper extremity dystonia, adductor laryngeal dystonia, and upper extremity essential tremor (Level B), and may be considered for hemifacial spasm, focal lower limb dystonia, and motor tics (Level C). While clinicians' practice may suggest stronger recommendations in some of these indications, evidence-based conclusions are limited by the availability of data.

Original languageEnglish (US)
Pages (from-to)1699-1706
Number of pages8
JournalNeurology
Volume70
Issue number19
DOIs
StatePublished - May 2008
Externally publishedYes

Fingerprint

Biomedical Technology Assessment
Dystonia
Neurotoxins
Movement Disorders
Upper Extremity
Blepharospasm
Hemifacial Spasm
Essential Tremor
Torticollis
Tics
Lower Extremity
Therapeutics
MEDLINE
Safety

ASJC Scopus subject areas

  • Clinical Neurology

Cite this

Assessment : botulinum neurotoxin for the treatment of movement disorders (an evidence-based review): Report of the therapeutics and technology assessment subcommittee of the american academy of neurologysymbol. / Simpson, D. M.; Blitzer, A.; Brashear, A.; Comella, C.; Dubinsky, R.; Hallett, M.; Jankovic, J.; Karp, B.; Ludlow, C. L.; Miyasaki, J. M.; Naumann, M.; So, Y.

In: Neurology, Vol. 70, No. 19, 05.2008, p. 1699-1706.

Research output: Contribution to journalArticle

Simpson, D. M. ; Blitzer, A. ; Brashear, A. ; Comella, C. ; Dubinsky, R. ; Hallett, M. ; Jankovic, J. ; Karp, B. ; Ludlow, C. L. ; Miyasaki, J. M. ; Naumann, M. ; So, Y. / Assessment : botulinum neurotoxin for the treatment of movement disorders (an evidence-based review): Report of the therapeutics and technology assessment subcommittee of the american academy of neurologysymbol. In: Neurology. 2008 ; Vol. 70, No. 19. pp. 1699-1706.
@article{b8a4244c72cd47879a52e91fa33f9a8f,
title = "Assessment: botulinum neurotoxin for the treatment of movement disorders (an evidence-based review): Report of the therapeutics and technology assessment subcommittee of the american academy of neurologysymbol",
abstract = "To perform an evidence-based review of the safety and efficacy of botulinum neurotoxin (BoNT) in the treatment of movement disorders. A literature search was performed including MEDLINE and Current Contents for therapeutic articles relevant to BoNT and selected movement disorders. Authors reviewed, abstracted, and classified articles based on American Academy of Neurology criteria (Class I-IV). The highest quality literature available for the respective indications was as follows: blepharospasm (two Class II studies); hemifacial spasm (one Class II and one Class III study); cervical dystonia (seven Class I studies); focal upper extremity dystonia (one Class I and three Class II studies); focal lower extremity dystonia (one Class II study); laryngeal dystonia (one Class I study); motor tics (one Class II study); and upper extremity essential tremor (two Class II studies). Botulinum neurotoxin should be offered as a treatment option for the treatment of cervical dystonia (Level A), may be offered for blepharospasm, focal upper extremity dystonia, adductor laryngeal dystonia, and upper extremity essential tremor (Level B), and may be considered for hemifacial spasm, focal lower limb dystonia, and motor tics (Level C). While clinicians' practice may suggest stronger recommendations in some of these indications, evidence-based conclusions are limited by the availability of data.",
author = "Simpson, {D. M.} and A. Blitzer and A. Brashear and C. Comella and R. Dubinsky and M. Hallett and J. Jankovic and B. Karp and Ludlow, {C. L.} and Miyasaki, {J. M.} and M. Naumann and Y. So",
year = "2008",
month = "5",
doi = "10.1212/01.wnl.0000311389.26145.95",
language = "English (US)",
volume = "70",
pages = "1699--1706",
journal = "Neurology",
issn = "0028-3878",
publisher = "Lippincott Williams and Wilkins",
number = "19",

}

TY - JOUR

T1 - Assessment

T2 - botulinum neurotoxin for the treatment of movement disorders (an evidence-based review): Report of the therapeutics and technology assessment subcommittee of the american academy of neurologysymbol

AU - Simpson, D. M.

AU - Blitzer, A.

AU - Brashear, A.

AU - Comella, C.

AU - Dubinsky, R.

AU - Hallett, M.

AU - Jankovic, J.

AU - Karp, B.

AU - Ludlow, C. L.

AU - Miyasaki, J. M.

AU - Naumann, M.

AU - So, Y.

PY - 2008/5

Y1 - 2008/5

N2 - To perform an evidence-based review of the safety and efficacy of botulinum neurotoxin (BoNT) in the treatment of movement disorders. A literature search was performed including MEDLINE and Current Contents for therapeutic articles relevant to BoNT and selected movement disorders. Authors reviewed, abstracted, and classified articles based on American Academy of Neurology criteria (Class I-IV). The highest quality literature available for the respective indications was as follows: blepharospasm (two Class II studies); hemifacial spasm (one Class II and one Class III study); cervical dystonia (seven Class I studies); focal upper extremity dystonia (one Class I and three Class II studies); focal lower extremity dystonia (one Class II study); laryngeal dystonia (one Class I study); motor tics (one Class II study); and upper extremity essential tremor (two Class II studies). Botulinum neurotoxin should be offered as a treatment option for the treatment of cervical dystonia (Level A), may be offered for blepharospasm, focal upper extremity dystonia, adductor laryngeal dystonia, and upper extremity essential tremor (Level B), and may be considered for hemifacial spasm, focal lower limb dystonia, and motor tics (Level C). While clinicians' practice may suggest stronger recommendations in some of these indications, evidence-based conclusions are limited by the availability of data.

AB - To perform an evidence-based review of the safety and efficacy of botulinum neurotoxin (BoNT) in the treatment of movement disorders. A literature search was performed including MEDLINE and Current Contents for therapeutic articles relevant to BoNT and selected movement disorders. Authors reviewed, abstracted, and classified articles based on American Academy of Neurology criteria (Class I-IV). The highest quality literature available for the respective indications was as follows: blepharospasm (two Class II studies); hemifacial spasm (one Class II and one Class III study); cervical dystonia (seven Class I studies); focal upper extremity dystonia (one Class I and three Class II studies); focal lower extremity dystonia (one Class II study); laryngeal dystonia (one Class I study); motor tics (one Class II study); and upper extremity essential tremor (two Class II studies). Botulinum neurotoxin should be offered as a treatment option for the treatment of cervical dystonia (Level A), may be offered for blepharospasm, focal upper extremity dystonia, adductor laryngeal dystonia, and upper extremity essential tremor (Level B), and may be considered for hemifacial spasm, focal lower limb dystonia, and motor tics (Level C). While clinicians' practice may suggest stronger recommendations in some of these indications, evidence-based conclusions are limited by the availability of data.

UR - http://www.scopus.com/inward/record.url?scp=43149083728&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=43149083728&partnerID=8YFLogxK

U2 - 10.1212/01.wnl.0000311389.26145.95

DO - 10.1212/01.wnl.0000311389.26145.95

M3 - Article

C2 - 18458230

AN - SCOPUS:43149083728

VL - 70

SP - 1699

EP - 1706

JO - Neurology

JF - Neurology

SN - 0028-3878

IS - 19

ER -